...
首页> 外文期刊>British journal of clinical pharmacology >A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients
【24h】

A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients

机译:机械性心脏瓣膜置换患者中CYP2C9的单倍型与华法林敏感性相关

获取原文
   

获取外文期刊封面封底 >>

       

摘要

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT? CYP2C9 single nucleotide polymorphisms (SNPs) are important in safe and effective oral anticoagulation with warfarin use.? Although CYP2C9*2 and *3 are important genetic factors for the warfarin dose, one of the CYP2C9 SNPs, IVS-65G>C, has been suggested to be associated with warfarin sensitivity. However, as of yet, there has been no explanation about the possible mechanism and linkage analysis.WHAT THIS PAPER ADDS? New information on CYP2C9 SNPs and their occurrences in common haplotype structures in healthy unrelated Koreans and in individuals who require low warfarin dose after mechanical heart valve replacements (MHVRs) were studied.? Additional evidence showed that an Asian dominant haplotype consisting of -1565C>T, -1188T>C, IVS3+197G>A, IVS3-334C>T, IVS3-65G>C, IVS4-115A>G and IVS5-73A>G could be associated with a low warfarin maintenance dose in mechanical heart valve replacement (MHVR) patients.AIMSThe objectives of this study were to determine the distribution of CYP2C9 variants in Koreans and investigate their association with warfarin dose requirements in patients who received MHVRs.METHODSAll nine exons, intron–exon junction, and promoter region of CYP2C9 were amplified and directly sequenced in 50 healthy normal Koreans. Additional direct DNA sequencing of the CYP2C9 gene was conducted in 36 of the 267 MHVR patients who required low maintenance warfarin doses without carrying CYP2C9*3 and VKORC1 1173T mutations. The effects of CYP2C9 genetics on warfarin maintenance dose were assessed in 267 MHVR patients.RESULTSThirty-nine single nucleotide polymorphisms (SNPs) including seven previously unidentified SNPs were identified in 50 Koreans by direct DNA sequencing. One of the CYP2C9 haplotypes exhibited an association with warfarin low dose requirement. The adjusted odds ratio for the haplotype between the low dose group and the normal subjects was 2.5 (95% confidence interval 1.05, 6.16). This haplotype consisting of -1565C>T, -1188T>C, IVS3+197G>A, IVS3-334C>T, IVS3-65G>C, IVS4-115A>G, and IVS5-73A>G was found in 15% of 36 MHVR patients who required low warfarin doses, while 4% of 50 normal healthy subjects exhibited this haplotype. One of the SNPs comprising this haplotype, -1565C>T, apparently changed a protein binding pattern as observed in electrophoretic mobility shift assay.CONCLUSIONThe haplotype including -1565C>T, -1188T>C, IVS3+197G>A, IVS3-334C>T, IVS3-65G>C, IVS4-115A>G, and IVS5-73A>G seems to be associated with low warfarin dose requirement and this haplotype could be considered in the development of a warfarin dose prediction model for Asian populations.
机译:此主题已经知道什么? CYP2C9单核苷酸多态性(SNP)在使用华法林的安全有效口服抗凝剂中很重要。尽管CYP2C9 * 2和* 3是华法林剂量的重要遗传因素,但已有人提出一种CYP2C9 SNP(IVS-65G> C)与华法林敏感性有关。但是,到目前为止,还没有关于可能的机理和连锁分析的解释。研究了有关CYP2C9 SNP及其在不相关的健康韩国人和机械心脏瓣膜置换术(MHVR)后需要低华法林剂量的个体中常见单倍型结构中的发生情况的新信息。其他证据表明,由-1565C> T,-1188T> C,IVS3 + 197G> A,IVS3-334C> T,IVS3-65G> C,IVS4-115A> G和IVS5-73A> G组成的亚洲优势单倍型可以AIMS本研究的目的是确定韩国人中CYP2C9变异体的分布,并调查其与接受MHVR的患者中华法林剂量需求的相关性。方法所有九个外显子,CYP2C9的内含子-外显子连接和启动子区域被扩增并直接测序在50名健康的正常韩国人中。 CYP2C9基因的其他直接DNA测序在267名MHVR患者中进行,这些患者需要低维持剂量的华法林,且不携带CYP2C9 * 3和VKORC1 1173T突变。评估了267例MHVR患者中CYP2C9遗传学对华法林维持剂量的影响。结果通过直接DNA测序在50名韩国人中鉴定出39个单核苷酸多态性(SNP),包括7个先前未鉴定的SNP。 CYP2C9单倍型之一显示与华法林低剂量需求相关。低剂量组和正常受试者之间的单倍型调整比值比为2.5(95%置信区间1.05、6.16)。在15%的样本中发现了由-1565C> T,-1188T> C,IVS3 + 197G> A,IVS3-334C> T,IVS3-65G> C,IVS4-115A> G和IVS5-73A> G组成的单倍型。 36名需要低华法林剂量的MHVR患者,而50名正常健康受试者中有4%表现出这种单倍型。如电泳迁移率变动分析所观察到的,包含这种单倍型的SNP之一-1565C> T明显改变了蛋白质结合模式。结论结论-1565C> T,-1188T> C,IVS3 + 197G> A,IVS3-334C> T,IVS3-65G> C,IVS4-115A> G和IVS5-73A> G似乎与低华法林剂量需求有关,在开发亚洲人群的华法林剂量预测模型时可以考虑这种单倍型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号